FDA approves stem cell for first-in-human use in clinical trial

Kaitlyn Dmyterko | | Health Imaging | Screening
stem cell - 219.64 Kb
The FDA has approved a stem cell therapy that will work to repair damage caused by heart attacks, according to a release from the California Institute for Regenerative Medicine (CIRM). The approval will be the first-in-human use for the therapy in clinical trials.

According to the release, Los Angeles-based Capricor, which uses cardiosphere derived cells, will carry out the therapy, which aims to reduce scarring and repair the cells affected by heart attack. The biotechnology company stated on its website that its research only involves adult cells.

“This is the first time that research by a CIRM-funded disease team has resulted in an Investigational New Drug approval from the FDA, a critical step in testing promising therapies in patients,” Ellen Feigal, MD, senior vice president for research and development at the stem cell agency, said in a release. “It’s a reflection of the initial progress being made in advancing scientific discoveries towards potential therapies for patients.”

The therapy was funded by CIRM with a $5.5 million disease team award that was granted to a team at Cedars-Sinai Heart Institute in Los Angeles.

Kaitlyn Dmyterko

Related Content

What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise
Singing radiologist pens song to clear up confusion about breast cancer screening recs
AI loaded onto mammography systems can flag possible cancers in real time to speed workflows

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.